MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Moderna, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$226.89+8.88 (+4.07%)
Close on Oct 19, 2026
- Market cap
- $90.30B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$200.88 (+772.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Moderna, Inc. saw revenue fall 27.6% to $2.23B over the twelve months to Jun 30, 2026. Free cash flow was -$1.24B.
Revenue
$2.23B
-27.6% vs. a year earlier
Operating income
-$3.32B
TTM Q2 2026
Free cash flow
-$1.24B
TTM Q2 2026
EPS, diluted
-$7.99
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $90.30B
- P/E ratio
- –
- Price to sales
- 40.53
- Price to book
- 13.36
- Dividend yield
- –
- Free cash flow yield
- -1.38%
Fundamentals
- Revenue
- $2.23B
- Net income
- -$3.15B
- EPS, diluted
- -$7.99
- Free cash flow
- -$1.24B
- Book value per share
- $16.99
- Diluted shares
- 398M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$2.23B-27.6% YoY
Gross profit
$521.00M-67.8% YoY
Operating income
-$3.32B
Net income
-$3.15B
EPS, diluted
-$7.99
Free cash flow
-$1.24B
Reported periodTrailing twelve months